Icure Pharmaceutical Incorporation Cash Flow Quality Index
Icure Pharmaceutical Incorporation cash flow quality index. Icure Pharmaceutical Incorporation (175250) has a Cash Flow Quality Index of -689.55x as of December 2024. Operating cash flow of ₩-17.05 Billion is below net income of ₩24.73 Million, suggesting accrual-heavy earnings not yet converted to cash. See Icure Pharmaceutical Incorporation financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Icure Pharmaceutical Incorporation (2017–2024)
Cash flow quality index of Icure Pharmaceutical Incorporation from 2017 to 2024. Historical Cash Flow Quality Index for Icure Pharmaceutical Incorporation across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 175250 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Icure Pharmaceutical Incorporation Cash Flow Quality Index by Year (2017–2024)
Icure Pharmaceutical Incorporation cash flow quality index by year from 2017 to 2024. Year-by-year earnings quality comparison for Icure Pharmaceutical Incorporation. For the full cash flow conversion analysis, see 175250 operating cash flow.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -689.55x | ₩-17.05 Billion | ₩24.73 Million | ▼ -33240.2% |
| 2017 | 2.08x | ₩1.12 Billion | ₩537.95 Million | — |